Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Fixed dose combination of clopidogrel/Aspirin
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2012-08-13

Last Posted Date: 2012-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT01663038

Locations: 🇰🇷
Inje University Pusan Paik Hospital, Pusan, Korea, Republic of

Efficacy and Safety of CKD-828 to Stage 2 Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828 2.5/40mg
Drug: S-amlodipine 2.5mg
Drug: CKD-828 5/40mg
Drug: S-amlodipine 5mg
Drug: CKD-828 5/80mg

First Posted Date: 2012-07-06

Last Posted Date: 2013-06-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 103

Registration Number: NCT01634295

Locations: 🇰🇷
Seoul national university Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Topotecan
Drug: Belotecan

First Posted Date: 2012-06-28

Last Posted Date: 2016-09-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 141

Registration Number: NCT01630018

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Seoul Metropolitan, Korea, Republic of

Safety and Pharmacokinetic Profile of CKD-581

Phase 1

Completed

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: CKD-581

First Posted Date: 2012-04-19

Last Posted Date: 2016-10-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 39

Registration Number: NCT01580371

Locations: 🇰🇷
ASAN Medical Center, Seoul, Korea, Republic of

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: CKD-516 inj.

First Posted Date: 2012-03-22

Last Posted Date: 2015-09-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 21

Registration Number: NCT01560325

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

CKD-828 S-Amlodipine Non-Responder Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828 2.5/40mg
Drug: S-Amlodipine 2.5mg
Drug: CKD-828 2.5/80mg

First Posted Date: 2011-12-29

Last Posted Date: 2012-11-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 187

Registration Number: NCT01501253

Locations: 🇰🇷
Seoul St. Mary's hospital, The catholic university of Korea, Seoul, Korea, Republic of

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Topotecan
Drug: Belotecan

First Posted Date: 2011-12-23

Last Posted Date: 2018-12-27

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 164

Registration Number: NCT01497873

Locations: 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇰🇷
Chungbuk University Hospital, Daegu, Korea, Republic of
🇰🇷
Keimyung University Dongsan Center, Daegu, Korea, Republic of

and more 11 locations

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel and Aspirin
Drug: Fixed dose combination of clopidogrel/aspirin

First Posted Date: 2011-12-21

Last Posted Date: 2011-12-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT01496261

Locations: 🇰🇷
Inje University Pusan Paik Hospital, Jin-gu, Pusan, Korea, Republic of

CKD-828 Telmisartan Non-Responder Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan 80mg
Drug: CKD-828 40/2.5mg
Drug: CKD-828 40/5mg

First Posted Date: 2011-08-31

Last Posted Date: 2012-09-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 183

Registration Number: NCT01426100

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷
Ewha Womans University Hospital, Seoul, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of

and more 15 locations

Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule

Phase 1

Completed

Conditions: Chronic Stable Angina

Interventions: Drug: Dilatrend SR capsule

First Posted Date: 2011-06-09

Last Posted Date: 2012-02-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT01369472

Locations: 🇰🇷
Asan Medcial Center, Songpa-gu, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy